RNS Number : 8030A
NetScientific PLC
10 June 2016
 

 

 

("NetScientific" or the "Company" or the "Group")

 

Netscientific Confirms Start Date for Ian Postlethwaite as CFO  

 

London, UK - 10 June 2016 - NetScientific plc ("NetScientific", AIM:NSCI), the transatlantic biomedical and healthcare technology group, is pleased to confirm that further to the Company's announcement of his appointment on 5th April 2016, new Chief Financial Officer Ian Postlethwaite will join the Company on the 13th June 2016 and will join the Board immediately following the Company's Annual General Meeting on 15th June 2016.

 

Commenting on the appointment, Sir Richard Sykes, Chairman of NetScientific, said: "We are pleased to welcome Ian as our new Chief Financial Officer. This is an important period for NetScientific as we move forward with a renewed focus on digital health, diagnostics and therapeutics. Ian's extensive experience in the healthcare sector and the capital markets will prove invaluable as the Company continues to progress.

 

"I would like to take this opportunity to thank Mark Nanovich for his excellent contribution as Interim CFO during this period."

 

Ian Postlethwaite commented: "This is an exciting time to be joining NetScientific and I look forward to working with CEO, Francois Martelet and the management team to deliver value across our portfolio of high-quality assets focused on dynamic new areas in healthcare."

 

 

- Ends -

 

 

For more information, please contact:

 

NetScientific

François R. Martelet, M.D., CEO

Mark Nanovich, Interim CFO

 

Tel: +44 (0)20 3514 1800

Investec (NOMAD and broker)

Gary Clarence / Daniel Adams

Tel: +44 (0)20 7597 4000

 

Consilium Strategic Communications

Mary-Jane Elliott / Chris Gardner / Jessica Hodgson / Chris Welsh / Laura Thornton

 

Tel: +44 (0)20 3709 5700

netscientific@consilium-comms.com

 

 

About NetScientific Plc

 

NetScientific is a biomedical and healthcare technology group that funds and develops technologies that offer transformative benefits to people's lives and society through improved diagnosis, prognosis and treatment.  For more information, please visit the website at www.netscientific.net.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCDDGDLBSGBGLC